Toyoaki Hida

Toyoaki Hida

UNVERIFIED PROFILE

Are you Toyoaki Hida?   Register this Author

Register author
Toyoaki Hida

Toyoaki Hida

Publications by authors named "Toyoaki Hida"

Are you Toyoaki Hida?   Register this Author

100Publications

3311Reads

12Profile Views

Anaplastic lymphoma kinase expression in small-cell lung cancer.

Histopathology 2019 Jul 23;75(1):20-28. Epub 2019 May 23.

Department of Pathology and Molecular Diagnostics, Aichi Cancer Centre, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13842DOI Listing
July 2019

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.

Eur J Cancer 2019 May 13;113:78-86. Epub 2019 Apr 13.

Department of Thoracic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.03.012DOI Listing
May 2019

Salvage surgery for small cell lung cancer after chemoradiotherapy.

Jpn J Clin Oncol 2019 Apr;49(4):389-392

Department of Thoracic Surgery, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyz010DOI Listing
April 2019

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.

Authors:
Toyoaki Hida

Ther Adv Respir Dis 2018 Jan-Dec;12:1753466618801167

Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1753466618801167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156204PMC
March 2019

Inflammation Flare and Radiation Necrosis Around a Stereotactic Radiotherapy-Pretreated Brain Metastasis Site After Nivolumab Treatment.

J Thorac Oncol 2018 12 12;13(12):1975-1978. Epub 2018 Jul 12.

Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183078
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.07.005DOI Listing
December 2018

Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.

Lung Cancer 2018 11 3;125:212-217. Epub 2018 Oct 3.

Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya, Aichi 464-8681, Japan. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183058
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.10.001DOI Listing
November 2018

Durvalumab showed long and durable effects after chemoradiotherapy in stage III non-small cell lung cancer: results of the PACIFIC study.

J Thorac Dis 2018 Apr;10(Suppl 9):S1108-S1112

Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.03.180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5949402PMC
April 2018

[Result of Clinical Trials of Ceritinib in Patients with ALK-Rearranged Non-Small-Cell Lung Cancer and Management of the Adverse Events].

Gan To Kagaku Ryoho 2018 Feb;45(2):257-264

Dept. of Thoracic Oncology, Hyogo Cancer Center.

View Article

Download full-text PDF

Source
February 2018

Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.

Clin Lung Cancer 2017 11 10;18(6):698-705.e2. Epub 2017 May 10.

Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2017.05.004DOI Listing
November 2017

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 11 31;12(11):1733-1736. Epub 2017 Jul 31.

Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.07.025DOI Listing
November 2017

Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2017 Nov 13;35(32):3662-3670. Epub 2017 Sep 13.

Kaoru Kubota, Nippon Medical School; Kaori Hara and Takayuki Asato, Takeda Pharmaceutical, Tokyo; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Fumihiro Oshita, Kanagawa Prefectural Ashigarakami Hospital, Matsuda; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Kiyotaka Yoh, National Cancer Center Hospital East, Chiba; Hidetoshi Hayashi, Hiroyasu Kaneda, and Kazuhiko Nakagawa, Kindai University Faculty of Medicine; Hidetoshi Hayashi, Kishiwada Municipal Hospital, Osaka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama; Kazuhiko Yamada, Kurume University School of Medicine; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Hiroshi Tanaka, Niigata Cancer Center Hospital, Niigata, Japan; Keunchil Park, Samsung Biomedical Research Institute, Seoul; Eun Kyung Cho, Gachon University; Kyung-Hee Lee, Inha University Hospital, Incheon, South Korea; Chih-Bin Lin, Buddhist Tzu-Chi General Hospital, Hualien; James Chih-Hsin Yang, National Taiwan University Hospital; National Taiwan University Cancer Center, Taipei City, Peoples Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.7297DOI Listing
November 2017

Clinical Efficacy of Alectinib in Patients with -Rearranged Non-small Cell Lung Cancer After Ceritinib Failure.

Anticancer Res 2017 11;37(11):6477-6480

Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.12103DOI Listing
November 2017

Alectinib can replace crizotinib as standard first-line therapy for -positive lung cancer.

Ann Transl Med 2017 Nov;5(21):433

Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2017.08.36DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690958PMC
November 2017

Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer.

Case Rep Oncol 2017 Sep-Dec;10(3):802-808. Epub 2017 Sep 6.

Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000479960DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649270PMC
September 2017

Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.

Cancer 2017 05 8;123(10):1731-1740. Epub 2017 Feb 8.

Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.30539DOI Listing
May 2017

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer: AF-001JP.

J Clin Oncol 2017 May 15;35(14):1515-1521. Epub 2017 Mar 15.

Tomohide Tamura, St Luke's International Hospital; Yuichiro Ohe, National Cancer Center Hospital; Hiroshi Kuriki, Tadashi Shimada, and Tomohiro Tanaka, Chugai Pharmaceutical; Kengo Takeuchi, Japanese Foundation for Cancer Research; Makoto Nishio, The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo; Katsuyuki Kiura, Okayama University Hospital, Okayama; Takashi Seto, National Kyusyu Cancer Center, Fukuoka; Kazuhiko Nakagawa, Kindai University, Osaka-Sayama; Makoto Maemondo, Miyagi Cancer Center, Natori; Akira Inoue, Tohoku University, Sendai; Toyoaki Hida, Aichi Cancer Center, Nagoya; Hiroshige Yoshioka, Kurashiki Central Hospital, Kurashiki; Masao Harada, Hokkaido Cancer Center, Sapporo; Naoyuki Nogami, National Hospital Organization Shikoku Cancer Center, Matsuyama; and Haruyasu Murakami, Shizuoka Cancer Center, Shizuoka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.5749DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455704PMC
May 2017

Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence.

Med Oncol 2017 Mar 30;34(3):34. Epub 2017 Jan 30.

Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12032-017-0895-4DOI Listing
March 2017

Diagnosis by Volatile Organic Compounds in Exhaled Breath from Lung Cancer Patients Using Support Vector Machine Algorithm.

Sensors (Basel) 2017 Feb 4;17(2). Epub 2017 Feb 4.

Department of Materials and Chemistry, National Institute of Advanced Industrial Science and Technology (AIST), Shimo-Shidami, Moriyama-ku, Nagoya 463-8560, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/s17020287DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5335963PMC
February 2017

Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.

Cancer Lett 2017 01 20;385:215-224. Epub 2016 Oct 20.

Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan; Department of Cancer Genetics, Program in Function Construction Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043835163064
Publisher Site
http://dx.doi.org/10.1016/j.canlet.2016.10.020DOI Listing
January 2017

Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.

J Clin Oncol 2016 08 18;34(24):2866-73. Epub 2016 Jul 18.

Lucio Crinò, University Medical School of Perugia, Azienda Ospedale Perugia, Perugia; Filippo De Marinis, European Institute of Oncology, Milan; Giorgio Scagliotti, University of Torino, Torino, Italy; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands; Heather Wakelee, Stanford University Medical Center, Stanford, CA; Toyoaki Hida, Aichi Cancer Center, Nagoya; Makoto Nishio, Japanese Foundation for Cancer Research, Tokyo, Japan; Tony Mok, Chinese University of Hong Kong, Shatin, China; David Spigel, Sarah Cannon Research Institute, Nashville, TN; Enriqueta Felip, Vall d'Hebron University, Barcelona, Spain; Fabrice Branle and Massimiliano Quadrigli, Novartis Pharma AG, Basel, Switzerland; Chetachi Emeremni and Jie Zhang, Novartis Pharma, East Hanover, NJ; and Alice T. Shaw, Massachusetts General Hospital, Boston MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2015.65.5936
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.65.5936DOI Listing
August 2016

Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.

Anticancer Drugs 2016 07;27(6):573-5

Departments of aThoracic OncologybPathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/anti-cancerdrugs/2016/07000/Rap
Web Search
http://dx.doi.org/10.1097/CAD.0000000000000356DOI Listing
July 2016

Clinical impact of crizotinib on central nervous system progression in ALK-positive non-small lung cancer.

Lung Cancer 2016 07 23;97:43-7. Epub 2016 Apr 23.

Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2016.04.006DOI Listing
July 2016

Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women.

Authors:
Zhaoming Wang Wei Jie Seow Kouya Shiraishi Chao A Hsiung Keitaro Matsuo Jie Liu Kexin Chen Taiki Yamji Yang Yang I-Shou Chang Chen Wu Yun-Chul Hong Laurie Burdett Kathleen Wyatt Charles C Chung Shengchao A Li Meredith Yeager Amy Hutchinson Wei Hu Neil Caporaso Maria T Landi Nilanjan Chatterjee Minsun Song Joseph F Fraumeni Takashi Kohno Jun Yokota Hideo Kunitoh Kyota Ashikawa Yukihide Momozawa Yataro Daigo Tetsuya Mitsudomi Yasushi Yatabe Toyoaki Hida Zhibin Hu Juncheng Dai Hongxia Ma Guangfu Jin Bao Song Zhehai Wang Sensen Cheng Zhihua Yin Xuelian Li Yangwu Ren Peng Guan Jiang Chang Wen Tan Chien-Jen Chen Gee-Chen Chang Ying-Huang Tsai Wu-Chou Su Kuan-Yu Chen Ming-Shyan Huang Yuh-Min Chen Hong Zheng Haixin Li Ping Cui Huan Guo Ping Xu Li Liu Motoki Iwasaki Taichi Shimazu Shoichiro Tsugane Junjie Zhu Gening Jiang Ke Fei Jae Yong Park Yeul Hong Kim Jae Sook Sung Kyong Hwa Park Young Tae Kim Yoo Jin Jung Chang Hyun Kang In Kyu Park Hee Nam Kim Hyo-Sung Jeon Jin Eun Choi Yi Young Choi Jin Hee Kim In-Jae Oh Young-Chul Kim Sook Whan Sung Jun Suk Kim Ho-Il Yoon Sun-Seog Kweon Min-Ho Shin Adeline Seow Ying Chen Wei-Yen Lim Jianjun Liu Maria Pik Wong Victor Ho Fun Lee Bryan A Bassig Margaret Tucker Sonja I Berndt Wong-Ho Chow Bu-Tian Ji Junwen Wang Jun Xu Alan Dart Loon Sihoe James C M Ho John K C Chan Jiu-Cun Wang Daru Lu Xueying Zhao Zhenhong Zhao Junjie Wu Hongyan Chen Li Jin Fusheng Wei Guoping Wu She-Juan An Xu-Chao Zhang Jian Su Yi-Long Wu Yu-Tang Gao Yong-Bing Xiang Xingzhou He Jihua Li Wei Zheng Xiao-Ou Shu Qiuyin Cai Robert Klein William Pao Charles Lawrence H Dean Hosgood Chin-Fu Hsiao Li-Hsin Chien Ying-Hsiang Chen Chung-Hsing Chen Wen-Chang Wang Chih-Yi Chen Chih-Liang Wang Chong-Jen Yu Hui-Ling Chen Yu-Chun Su Fang-Yu Tsai Yi-Song Chen Yao-Jen Li Tsung-Ying Yang Chien-Chung Lin Pan-Chyr Yang Tangchun Wu Dongxin Lin Baosen Zhou Jinming Yu Hongbing Shen Michiaki Kubo Stephen J Chanock Nathaniel Rothman Qing Lan

Hum Mol Genet 2016 Feb 4;25(3):620-9. Epub 2016 Jan 4.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA.

View Article

Download full-text PDF

Source
http://hmg.oxfordjournals.org/content/early/2016/01/06/hmg.d
Web Search
http://www.hmg.oxfordjournals.org/lookup/doi/10.1093/hmg/ddv
Publisher Site
http://dx.doi.org/10.1093/hmg/ddv494DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4731021PMC
February 2016

Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations.

J Thorac Oncol 2015 Jan;10(1):59-66

*Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan; †Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Aichi, Japan; ‡Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; §Thoracic Surgery, Aichi Cancer Center Hospital, Aichi, Japan; ‖Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan; ¶VCU Philips Institute for Oral Health Research, School of Dentistry and Massey Cancer Center, Virginia Commonwealth University, Richmond, VA; #Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Aichi, Japan; **Department of Surgery, Division of Thoracic Surgery, Kinki University Faculty of Medicine, Osaka-Sayama, Japan; and ††Department of Preventive Medicine, Kyushu University Faculty of Medical Sciences, Fukuoka, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000371DOI Listing
January 2015

Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.

J Clin Oncol 2014 Apr 17;32(12):1262-8. Epub 2014 Mar 17.

Miyako Satouchi, Hyogo Cancer Center, Akashi; Yoshikazu Kotani, Kobe University Graduate School of Medicine, Kobe; Taro Shibata and Haruhiko Fukuda, Japan Clinical Oncology Group Data Center, Multi-Institutional Clinical Trial Support Center, National Cancer Center; Yuichiro Ohe, National Cancer Center Hospital East; Makoto Nishio, Cancer Institute Hospital, Japanese Foundation For Cancer Research; Tomohide Tamura, National Cancer Center Hospital; Nagahiro Saijo, Japanese Society of Medical Oncology, Tokyo; Masahiko Ando, Kyoto University School of Public Health, Kyoto; Kazuhiko Nakagawa, Kinki University School of Medicine; Koji Takeda, Osaka City General Hospital; Tatsuo Kimura, Graduate School of Medicine, Osaka City University; Shinji Atagi, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Yukito Ichinose, National Hospital Organization Kyushu Cancer Center, Fukuoka; Toyoaki Hida, Aichi Cancer Center, Nagoya; Koichi Minato, Gunma Cancer Center, Gunma; and Akira Yokoyama, Niigata Cancer Center Hospital, Niigata, Japan.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2013.53.5153
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.53.5153DOI Listing
April 2014

EGFR exon 19 insertions show good response to gefitinib, but short time to progression in Japanese patients.

J Thorac Oncol 2014 Feb;9(2):e10-1

Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0b013e3182a735ccDOI Listing
February 2014

LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.

J Clin Oncol 2013 Sep 1;31(27):3335-41. Epub 2013 Jul 1.

Nobuyuki Katakami, Kobe City Medical Center General Hospital, Kobe; Shinji Atagi, National Hospital Organization Kinki-Chuo Chest Medical Center; Koji Takeda, Osaka City General Hospital; Kazuto Nishio, Kinki University, Osaka; Koichi Goto, National Cancer Center Hospital East, Chiba; Toyoaki Hida, Aichi Cancer Center Hospital, Nagoya; Takeshi Horai, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo; Akira Inoue, Tohoku University Hospital, Sendai; Yukito Ichinose, National Kyushu Cancer Center, Fukuoka; Kunihiko Koboyashi, Saitama International Medical Center, Saitama; Katsuyuki Kiura, Okayama University, Okayama; Yoko Seki and Ryuichi Ebisawa, Nippon Boehringer Ingelheim; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka, Japan; and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.45.0981DOI Listing
September 2013

Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib.

Lung Cancer 2013 Sep 25;81(3):495-496. Epub 2013 Jul 25.

Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8681, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2013.06.017DOI Listing
September 2013

HNF4α as a marker for invasive mucinous adenocarcinoma of the lung.

Am J Surg Pathol 2013 Feb;37(2):211-8

Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0b013e31826be303DOI Listing
February 2013

Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer.

Int J Clin Oncol 2012 Jun 30;17(3):218-24. Epub 2011 Jun 30.

Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10147-011-0277
Web Search
http://link.springer.com/10.1007/s10147-011-0277-4
Publisher Site
http://dx.doi.org/10.1007/s10147-011-0277-4DOI Listing
June 2012

The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors.

Jpn J Clin Oncol 2011 Sep 10;41(9):1067-73. Epub 2011 Aug 10.

Osaka City General Hospital, 2-13-22 Miyakojimahondori, Miyakojima-ku, Osaka 534-0021, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jjco/hyr110DOI Listing
September 2011

LATS2 is a tumor suppressor gene of malignant mesothelioma.

Cancer Res 2011 Feb 18;71(3):873-83. Epub 2011 Jan 18.

Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-2164DOI Listing
February 2011

Relationship of mRNA expressions of RanBP2 and topoisomerase II isoforms to cytotoxicity of amrubicin in human lung cancer cell lines.

Cancer Chemother Pharmacol 2010 Jul 7;66(2):237-43. Epub 2009 Oct 7.

Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-009-1151-1
Publisher Site
http://dx.doi.org/10.1007/s00280-009-1151-1DOI Listing
July 2010

Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.

J Cancer Res Clin Oncol 2010 Apr 24;136(4):527-35. Epub 2009 Sep 24.

Department of Thoracic Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-009-0685-2DOI Listing
April 2010

Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese population.

Carcinogenesis 2010 Apr 21;31(4):660-5. Epub 2010 Jan 21.

Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya 464-8618, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgq021DOI Listing
April 2010

The impact of radiation dose and fractionation on outcomes for limited-stage small-cell lung cancer.

Int J Radiat Oncol Biol Phys 2010 Mar 6;76(4):1121-6. Epub 2009 Aug 6.

Department of Radiation Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusaku, Nagoya 464-8681, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2009.03.069DOI Listing
March 2010

hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type.

J Hum Genet 2009 Dec 30;54(12):739-45. Epub 2009 Oct 30.

Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jhg.2009.108DOI Listing
December 2009